盐酸埃克替尼上市后，深入推进临床研究，助力中国肺癌研究走上国际舞台，开展了80多项学术研究，包括一线治疗研究、肺癌伴脑转移研究、EGFR状态不明患者研究、EGFR21外显子敏感突变加量研究、与化疗联合的研究、术后辅助治疗研究等，发表SCI论文200多篇，影响因子700多分，并在ASCO、WCLC、ESMO等国际学术会议上报告、展示。
盐酸埃克替尼改变了我国晚期肺癌治疗指南，树立了一线治疗标准，形成了埃克替尼在晚期非小细胞肺癌临床应用的专家共识，被纳入MIMS 《恶性肿瘤用药指南》、国家卫生计划生育委员会2018《中国原发性肺癌诊疗规范》、CSCO 2019原发性肺癌诊疗指南、卫健委《2019肿瘤用药指南原则》等。
相关文献
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
- Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
- First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
- Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study
- Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
- A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
- Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study
